ENR

5.88%

40.0¢ encounter resources limited

i never know what you are saying on any of my assets. Although I...

First 45 Last

Share
Profile

Follow
Christian Dyor

7,133 Posts.

572

28/06/23

11:29

Post #: 68509368
Share

Originally posted by 2ic: ↑

Straw pole out of interest. The ASX allows companies to pick and choose when to release handheld XRF results. Mostly it suits companies to keep it private, though everyone knows these results will be whispered and leaked because people talk, CR brokers are on the phone or having private briefings with management etc. We also know that for elements like REO and Nb that handXRF have a very low detection limit (5ppm for Nb when 1% Nb = 10,000ppm), so regardless of the 'repeatable accuracy' vs final lab assays, for all intent and purpose the handXRF results tell us early stage what the tenor of a discovery is.

One recent example from DRE, where they chose to release handXRF TREO results months before lab assays to prove they were onto a large high grade discovery.

"as expected", everyone knows that the variability between handXRF and the lab is both not significant and can be further reduced by calibration and a correlation adjustment factor. ASX argues that handXRF is unreliable and thus doesn;t have to be released, when obviously the variability is not usually relevant. Even if the handXRF was so wildly off as to be grossly misleading, so be it imo. Better everyone (insiders and outsiders) gets the info to consider and punt how they like then have material information undisclosed when 'continuous disclosure' is supposed to be the foundation of ASX markets bets practice (I know ).

Do readers think prefect should the enemy of the good (release no handXRF just in case it's misleading compared to lab assays 2-3 months away) leaving the market uninformed, or good better than hiding behind the perfect (release material handXRF results in early-stage discoveries so everyone is trading off the same level of information)??

GLTAH

Expand

i never know what you are saying on any of my assets. Although I never really read the self importance projected is far to much for me . Not on blocked though cause sometimes you are interesting

ENR Price at posting: 33.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 153 more messages in this thread...

First 45 Last

Add ENR (ASX) to my watchlist

(20min delay)
Last 40.0¢		Change -0.025(5.88%)		Mkt cap ! $180.7M

Open	High	Low	Value	Volume
42.5¢	42.5¢	39.0¢	$229.4K	572.5K

Buyers (Bids)

No.	Vol.	Price($)
1	1995	40.0¢

Sellers (Offers)

Price($)	Vol.	No.
41.0¢	5000	1

View Market Depth

No.	Vol.	Price($)
1	1995	0.400
1	44979	0.390
2	3551	0.380
4	16310	0.370
1	3000	0.365

Price($)	Vol.	No.
0.425	24669	1
0.435	26759	2
0.445	6660	1
0.450	12500	1
0.455	37800	2

Last trade - 15.58pm 04/10/2024 (20 minute delay)

ENR (ASX) Chart

i never know what you are saying on any of my assets. Although I...

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

i never know what you are saying on any of my assets. Although I...

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News